A New Risk Score Based on Lipid Indicators for Patients with Advanced Hepatocellular Carcinoma

  • 0Department of Medical Oncology, Peking University International Hospital, Beijing, People's Republic of China.

|

|

Summary

This summary is machine-generated.

A new risk score using lipid markers improves prognosis prediction for advanced hepatocellular carcinoma (HCC). This score aids in assessing patient outcomes and durable clinical benefit more effectively than existing methods.

Area Of Science

  • Hepatology
  • Oncology
  • Biochemistry

Background

  • Advanced hepatocellular carcinoma (HCC) presents a challenging prognosis.
  • Existing prognostic scores for HCC may lack sufficient positive predictive value.
  • There is a need for efficient tools to assess prognosis and clinical response in HCC patients.

Purpose Of The Study

  • To develop a novel, rapid, and effective risk score for advanced HCC.
  • To evaluate the score's ability to predict prognosis and clinical response.
  • To identify key prognostic variables in HCC.

Main Methods

  • Retrospective analysis of 391 HCC patients (2015-2024), divided into training and validation cohorts.
  • Utilized X-tile software for risk group stratification.
  • Employed COX proportional risk model, Kaplan-Meier analysis, time-dependent ROC curves, and nomogram analysis.

Main Results

  • Free fatty acid/high-density lipoprotein cholesterol (FFHL), tumor size, and BCLC stage were independent prognostic factors for overall survival (OS).
  • The developed risk score demonstrated significant prognostic value (p < 0.001) in both groups.
  • The score showed high predictive accuracy for progress-free survival (PFS) and OS, with AUCs ranging from 0.592 to 0.981.
  • The score provided a more accurate evaluation of durable clinical benefit (DCB) compared to best overall response (BOR).

Conclusions

  • A novel risk score incorporating lipid markers is a valuable tool for HCC prognosis.
  • This score effectively distinguishes patients who will achieve durable clinical benefit.
  • The developed score offers an improved method for assessing treatment response and patient outcomes in advanced HCC.